期刊文献+

SSTR2和SSTR5在喉癌中的表达及意义

Expression of somatostatin receptor subtype SSTR2 and SSTR5 in laryngeal carcinoma
下载PDF
导出
摘要 目的研究生长抑素受体(somatostatin receptor,SSTR)亚型SSTR2和SSTR5在喉癌组织及癌旁组织中的表达情况,以及与临床病理特征的关系。方法应用免疫组化方法检测46例喉癌组织与30例癌旁组织中SSTR2和SSTR5的表达,分析其与临床病理因素的关系。结果在46例喉癌中SSTR2和SSTR5的表达率分别为58.70%和82.61%,癌旁组织中分别为83.33%和90.00%。喉癌中SSTR2的表达低于癌旁组织(P<0.05),SSTR5的表达与癌旁组织无差异(P>0.05),SSTR2和SSTR5的表达与喉癌的临床分期(P<0.05)、病理分化程度(P<0.05)有明显相关。结论大多数喉癌肿瘤组织中有一种以上生长抑素受体亚型基因的表达,其表达随喉癌恶性程度呈下降趋势。 Objective To determinate whether human laryngeal carcinoma express somatostatin receptor subtype 2 (SSTR2) and 5 (SSTRS) and their relationship with clinical and pathological facts. Methods Immunochemistry was used to examine the expression of SSTR2 and SSTR5 in 46 cases of laryngeal carcinoma and 30 cases of adjacent tissues of cancer,theirs correlation with clinical and pathological facts were also analyzed. Results The positive expression rates of SSTR2 and SSTR5 were 58.70 % and 82.61% in carcinoma cells, 83.33 % and 90.00% in adjacent tissues of cancer. There was no significant difference in the positive rate of SSTR5, but the positive rate of SSTR2 in carcinoma cells was significantly lower titan that in adjacent tissue of cancer ( P 〈 0.05) . A significant correlation was found between SSTRs expression and tumor stage ( P 〈 0.05) ,tumor differentiation ( P 〈 0.05). Conclusion There were more than one SSTR subtypes in laryngeal carcinoma and the expression was declined with the malignant degree of laryngeal carcinoma.
出处 《中国实验诊断学》 2007年第7期871-874,共4页 Chinese Journal of Laboratory Diagnosis
关键词 喉癌 SSTR2 SSTR5 laryngeal carcinoma SSTR2 SSTR5
  • 相关文献

参考文献11

  • 1Szepeshazi K,Schally AV,Nagy A,et al.Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas[J].Cancer,2003,98(7):1401.
  • 2Szereday Z,Schally AV,Szepeshazi K,et al.Effective treatment of H838 human non-small cell lung carcinoma with a targetedcytotoxic somatostatin analog AN-238[J].Int J Oncol,2003,22(5):1141.
  • 3Zatelli MC,Piccin D,Tagliati F,et al.SRC homology-2-containing protein tyrosine phosphatase-1 restrains cellpmliferafion in human medullary thyroid carcinonm[J].Endocrinology,2005,146(6):2692.
  • 4Patel YC.Somatostatin and its receptor family[J].Front Neuroendocrinol,1999,20:157.
  • 5Florio T,Thellung S,Corsaro A,et al.Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenama cells in vitro[J].Clin Endocrinol (Oxf),2003,59(1):115.
  • 6Douziech N,Calro E,Coulombe Z,et al.Inhibitory and stimulatory effects of somatostatin two human pancreatic cancer cell lines:a primary role for tyrosine phosphatase SHP-1[J].Endocrinology,1999,140(2):765.
  • 7Kang B,Jeong K,Park S,et al.Regulation of apoptosis of by somatostatin and substance P in peritoneal macrophage[J].Regul Pept,2001,101(123):43.
  • 8Pola S,Cattaneo G,Vicentini LM.Antimigratory and antiinvasive effect of sumatostatin in human neuroblastoma cells:involvement of Racand MAP kinase activity[J].J Biol Chem,2003,278(42):40601.
  • 9Ren SG,TaylorJ,Dong J,et al.Functional association of sstr2 and sstr5 in suppression of growth hormone secretion.J Clin Endocrinol Metab[J].2003,88(9):4239.
  • 10Saveaun A,Gum G,Dufour H,et al.Bim-23244,a sumatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adonomas[J].J Clin Endocrinol Metab,2001,86(1):140.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部